Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The state legislature is mulling over the passage of two bills: one that would eliminate Ballad’s status as a protected monopoly, and another that would remove the Certificate of Need, a barrier that forces healthcare entities to submit expansion proposals to regulators for approval. The issue, the FTC says, is related to timing.
The Centers for Medicare & Medicaid Services unveiled a new program for alternative payment model participants that would allow clinicians to use products containing CBD as part of patient care plans. In response, the Food and Drug Administration vowed not to further restrict the sale of oral hemp products.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
On Tuesday, a judge formally rejected a motion by the company to have the case dismissed. Carelon Behavioral Health, a subsidiary of Elevance, is accused of publishing an inaccurate directory of providers for those seeking mental health services.
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
